{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:42:34Z","timestamp":1794397354498,"version":"4.9.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Michael J. Fox Foundation for Parkinson's Research"},{"name":"Natural Sciences and Engineering Research Council of Canada (NSERC), Parkinson Canada"},{"DOI":"10.13039\/100012456","name":"Toronto General & Western Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012456","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Allergan Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.11.016","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T12:15:27Z","timestamp":1542284127000},"page":"21-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Diagnostic biomarkers for Parkinson's disease: focus on \u03b1-synuclein in cerebrospinal fluid"],"prefix":"10.1016","volume":"59","author":[{"given":"Lorraine V.","family":"Kalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.016_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.parkreldis.2018.11.016_bib2","series-title":"Biomarkers in Risk Assessment: Validity and Validation","author":"International Programme on Chemical Safety","year":"2001"},{"key":"10.1016\/j.parkreldis.2018.11.016_bib3","series-title":"BEST (Biomarkers, EndpointS, and Other Tools) Resource","author":"FDA-NIH Biomarker Working Group","year":"2016"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mds.26438","article-title":"The NINDS Parkinson's disease biomarkers program","volume":"31","author":"Rosenthal","year":"2016","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/bmm-2016-0370","article-title":"Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program","volume":"11","author":"Gwinn","year":"2017","journal-title":"Biomark. Med."},{"issue":"6943","key":"10.1016\/j.parkreldis.2018.11.016_bib6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1136\/bmj.308.6943.1552","article-title":"Diagnostic tests 1: sensitivity and specificity","volume":"308","author":"Altman","year":"1994","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.parkreldis.2018.11.016_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.110.943860","article-title":"Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact","volume":"123","author":"Pletcher","year":"2011","journal-title":"Circulation"},{"issue":"7458","key":"10.1016\/j.parkreldis.2018.11.016_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","article-title":"Diagnostic tests 4: likelihood ratios","volume":"329","author":"Deeks","year":"2004","journal-title":"BMJ"},{"issue":"21","key":"10.1016\/j.parkreldis.2018.11.016_bib9","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1001\/jama.2011.713","article-title":"Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses","volume":"305","author":"Ioannidis","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.parkreldis.2018.11.016_bib10","series-title":"Fabry Disease: Perspectives from 5 Years of FOS","article-title":"Biomarkers in lysosomal storage diseases","author":"Cox","year":"2006"},{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.016_bib11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.neuron.2014.10.031","article-title":"Unbiased approaches to biomarker discovery in neurodegenerative diseases","volume":"84","author":"Chen-Plotkin","year":"2014","journal-title":"Neuron"},{"issue":"9996","key":"10.1016\/j.parkreldis.2018.11.016_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.parkreldis.2018.11.016_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11910-017-0737-y","article-title":"\u03b1-Synuclein and parkinsonism: updates and future perspectives","volume":"17","author":"Rosborough","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.016_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ng.3043","article-title":"Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease","volume":"46","author":"Nalls","year":"2014","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.016_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of \u03b1-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/mds.22464","article-title":"Biopsies of olfactory epithelium in patients with Parkinson's disease","volume":"24","author":"Witt","year":"2009","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.016_bib18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jnen\/nly056","article-title":"Immunohistochemical method and histopathology judging for the systemic synuclein sampling study (S4)","volume":"77","author":"Beach","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.11.016_bib19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson's disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"7","key":"10.1016\/j.parkreldis.2018.11.016_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00702-012-0784-0","article-title":"\u03b1-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system","volume":"119","author":"Mollenhauer","year":"2012","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.parkreldis.2018.11.016_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cca.2015.01.041","article-title":"Alzheimer's disease \u2014 recent biomarker developments in relation to updated diagnostic criteria","volume":"449","author":"H\u00f6glund","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.016_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2017.11","article-title":"CSF biomarkers for Alzheimer disease \u2014 approaching consensus","volume":"13","author":"Galasko","year":"2017","journal-title":"Nat. Rev. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2018.11.016_bib23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson's disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.016_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.11.016_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1212\/WNL.0000000000001308","article-title":"Parkinson disease with REM sleep behavior disorder","volume":"84","author":"Hu","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.11.016_bib26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00415-014-7560-z","article-title":"Correlates of cerebrospinal fluid levels of oligomeric- and total-\u03b1-synuclein in premotor, motor and dementia stages of Parkinson's disease","volume":"262","author":"Compta","year":"2015","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.11.016_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","article-title":"Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease","volume":"6","author":"Hansson","year":"2014","journal-title":"Alzheimer's Res. Ther."},{"issue":"121","key":"10.1016\/j.parkreldis.2018.11.016_bib28","doi-asserted-by":"crossref","first-page":"121ra20","DOI":"10.1126\/scitranslmed.3002566","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease","volume":"4","author":"Wang","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.11.016_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-015-0185-3","article-title":"Phosphorylated \u03b1-synuclein in Parkinson's disease: correlation depends on disease severity","volume":"3","author":"Stewart","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"20","key":"10.1016\/j.parkreldis.2018.11.016_bib30","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.11.016_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jnc.13390","article-title":"Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders","volume":"139","author":"Mollenhauer","year":"2016","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.11.016_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/mds.27090","article-title":"A user's guide for \u03b1-synuclein biomarker studies in biological fluids: perianalytical considerations","volume":"32","author":"Mollenhauer","year":"2017","journal-title":"Mov. Disord."},{"issue":"31","key":"10.1016\/j.parkreldis.2018.11.016_bib33","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1073\/pnas.0906759106","article-title":"Is Parkinson's disease a prion disorder?","volume":"106","author":"Olanow","year":"2009","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.11.016_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0166-2236(02)02195-1","article-title":"Cyclic amplification of protein misfolding: application to prion-related disorders and beyond","volume":"25","author":"Soto","year":"2002","journal-title":"Trends Neurosci."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.11.016_bib35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nmeth1066","article-title":"Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein","volume":"4","author":"Atarashi","year":"2007","journal-title":"Nat. Methods"},{"issue":"12","key":"10.1016\/j.parkreldis.2018.11.016_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001217","article-title":"Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays","volume":"6","author":"Wilham","year":"2010","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneurol.2016.65","article-title":"Advanced tests for early and accurate diagnosis of Creutzfeldt\u2013Jakob disease","volume":"12","author":"Zanusso","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.11.016_bib38","first-page":"3916","article-title":"Prion-like seeding of misfolded \u03b1-synuclein in the brains of dementia with Lewy body patients in RT-QUIC","volume":"55","author":"Sano","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.parkreldis.2018.11.016_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm.2294","article-title":"Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion","volume":"17","author":"Atarashi","year":"2011","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJMoa1315200","article-title":"A test for Creutzfeldt\u2013Jakob disease using nasal brushings","volume":"371","author":"Orr\u00fa","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.11.016_bib41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1056\/NEJMoa1404401","article-title":"Prions in the urine of patients with variant Creutzfeldt\u2013Jakob disease","volume":"371","author":"Moda","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parkreldis.2018.11.016_bib42","series-title":"Handbook of Clinical Neurology","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-444-63945-5.00019-2","article-title":"Prion protein amplification techniques","author":"Green","year":"2018"},{"issue":"10","key":"10.1016\/j.parkreldis.2018.11.016_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/acn3.338","article-title":"Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies","volume":"3","author":"Fairfoul","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2018.11.016_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.11.016_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of \u03b1-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T09:45:03Z","timestamp":1565257503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":45,"alternative-id":["S1353802018305145"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.016","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734486941.793553768","asserted-by":"object"}]},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic biomarkers for Parkinson's disease: focus on \u03b1-synuclein in cerebrospinal fluid","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}